/THIS NEWS RELEASE, PROVIDED PURSUANT TO APPLICABLE CANADIAN
REQUIREMENTS, IS NOT FOR DISTRIBUTION TO U.S. NEWS SERVICES OR FOR
DISSEMINATION IN THE UNITED
STATES, AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES
DESCRIBED HEREIN. THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER
THE UNITED STATES SECURITIES ACT
OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS, AND MAY NOT BE
OFFERED OR SOLD IN THE UNITED
STATES OR TO U.S. PERSONS ABSENT REGISTRATION OR APPLICABLE
EXEMPTION FROM REGISTRATION REQUIREMENTS./
VANCOUVER, Nov. 20, 2019 /CNW/ - Geyser Brands Inc.
(formerly Kanzen Capital Corp.) (TSX-V: GYSR) ("Geyser
Brands" or the "Company) is pleased to announce that the
Company's wholly-owned subsidiary, 0957102
B.C. Ltd. DBA Apothecary Botanicals ("Apothecary
Botanicals"), has been awarded a cannabis research license
(the "Research License") by Health Canada under the Cannabis
Regulations Act, allowing the Company to possess and produce
cannabis for the purpose of research.
With the awarded Research License, Geyser Brands will develop
new formulations for topicals, edibles, and beverages related
to cannabis. The Company has already completed all of its
research and planning for the next phase, and with the granting of
their Research License, will now commence converting the work into
real-life wellness products that have top-tier formulations. Geyser
Brands' fully operational R&D laboratory in Vancouver, BC will now develop cannabis-based
products as well as operate as a pilot-scale production for the
transformation of cannabis-CBD based ingredients and organic
formulations.
The license will enable Geyser Brands to move ahead with
research activities that involve direct handling of cannabis such
as SOP development, stability testing, sensory evaluation and
quality assurance for house brands and white label clients. Led by
Kuldip Gill, Chief Operating Officer
at Apothecary Botanicals, the research will be performed at
their Health Canada approved Licensed Production facility.
Andreas Thatcher, CEO commented,
"We are thrilled to announce that we have been awarded our Research
License from Health Canada. We now have the opportunity to act on
expanding our product development and innovation efforts through
new proprietary formulations with the intent to bring cannabis to
the mainstream. We look forward to working with some of our
existing partners to utilize our next phase of growth and
development at Geyser Brands."
The Research License is the third license granted to Geyser
Brands, after already receiving their Cultivation and Processing
Licenses in October 2018 and
June 2019, respectively. In addition,
the Company is in the process of obtaining their final license for
Medical and Retail Sales.
About Geyser Brands
Geyser Brands Inc. is a consumer health and wellness company
operating within the Canadian cannabis industry. Geyser's
proprietary delivery technologies include all natural
nano-technology, slow-release mechanisms, and non-molecule
degrading baking processes. The Company provides expertise from
conceptual innovation to manufacturing and end-use distribution.
Geyser owns a suite of several brands within the consumer-packaged
goods market that are offered nationwide at many recognized
retailers. Geyser Brands owns a Health Canada approved
Licensed Production facility and operates 15,000 sqft of
manufacturing space in two GMP facilities near Vancouver, BC.
For more information, visit Geyser Brands' website at
www.geyserbrands.com.
On Behalf of the Board of Directors
"Andreas Thatcher"
________________________________
Andreas Thatcher
Director and CEO
athatcher@geyserbrands.com
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
This news release contains forward‐looking
statements and forward‐looking information within the
meaning of applicable securities laws. These statements relate to
future events or future performance. All statements other than
statements of historical fact may be forward‐looking
statements or information. Forward‐looking statements
and information are often, but not always, identified by the use of
words such as "appear", "seek", "anticipate", "plan", "continue",
"estimate", "approximate", "expect", "may", "will", "project",
"predict", "potential", "targeting", "intend", "could", "might",
"should", "believe", "would" and similar expressions.
Forward-looking statements and information are provided for
the purpose of providing information about the current expectations
and plans of management of the Company relating to the future.
Readers are cautioned that reliance on such statements and
information may not be appropriate for other purposes, such as
making investment decisions. Since forward‐looking statements and
information address future events and conditions, by their very
nature they involve inherent risks and uncertainties. Actual
results could differ materially from those currently anticipated
due to a number of factors and risks. These include, but are not
limited to, the risks associated with the marijuana industry in
general such as operational risks in growing; competition;
incorrect assessment of the value and potential benefits of various
transactions; ability to access sufficient capital from internal
and external sources; failure to obtain required regulatory and
other approvals and changes in legislation, including but not
limited to tax laws and government regulations. Accordingly,
readers should not place undue reliance on the forward‐looking
statements, timelines and information contained in this news
release. Readers are cautioned that the foregoing list of factors
is not exhaustive. Additional information relating to Geyser is
available at www.sedar.com.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES
PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX
VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
SOURCE Geyser Brands Inc.